BioSpace News Archive

Between 40 and 50 percent of people with Parkinson’s will experience dyskinesia after just five years of taking levodopa. After ten years of taking the medication, this figure jumps to up to 80 percent

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the publication of results from the dose-ranging Phase 2 STAR Study of tolperisone in patients with acute and painful muscle spasms of the lower back, in the Journal of Pain Research. “The published clinical data

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced that its management team will participate in the 32nd Annual Piper Sandler Healthcare Conference.

LSO today announced the recipients of its 2021 LSO Awards, recognizing outstanding individuals and companies contributing to the success of Ontario’s life sciences sector

Vivaldi Biosciences, a clinical-stage biotechnology company developing genetically engineered intranasal vaccines for viral respiratory diseases, today announced it has filed a provisional patent application with the US Patent and Trademark Office for its Delta-19 combination vaccine for protection against SARS-CoV-2 (the virus responsible for Covid-19) and all strains of influenza virus.

The Washington Poison Center is warning parents of a dangerous trend in adolescent intentional overdose called the “Benadryl™ Challenge,” which encourages individuals to induce hallucinations by ingesting large amounts of Benadryl™.

Tarsius Pharma, a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, is pleased to announce that management will participate in the Piper Sandler 32nd Annual Healthcare Conference, being held virtually on November 30th to December 3rd, 2020

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2020.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2020.

Initiative addresses the accelerating shortage of nurses in the workforce and provides programs including scholarships for nurses and their children